Efficacy and safety of induction chemotherapy in oral cavity cancer: An eight-year experience at a Portuguese reference center

被引:0
|
作者
Barbosa-Martins, Joao [1 ]
Rolo, Ana [1 ]
Lima, Barbara [1 ]
Pereira, Jose Carlos [2 ]
Araujo, Claudia [2 ]
Guimaraes, Jorge [2 ]
Dinis, Jose [3 ]
Vieira, Claudia [3 ]
机构
[1] Hosp Senhora Oliveira, Med Oncol Dept, R Cutileiros 114, P-4835044 Guimaraes, Portugal
[2] Inst Portugues Oncol Porto Francisco Gentil, Surg Oncol, Porto, Portugal
[3] Inst Portugues Oncol Porto Francisco Gentil, Med Oncol Dept, Porto, Portugal
来源
TUMORI JOURNAL | 2024年 / 110卷 / 05期
关键词
Oral cavity cancer; squamous cell carcinoma; induction chemotherapy; toxicity; surgery; radiotherapy; PHASE-III TRIAL; NEOADJUVANT CISPLATIN; FLUOROURACIL; SURGERY; HEAD; DOCETAXEL;
D O I
10.1177/03008916241257099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Induction chemotherapy has been described as an option in locally advanced oral cavity squamous cell carcinoma when the surgical morbidity is expected to be high. This work aimed to evaluate the outcome and safety of induction chemotherapy in this setting. Methods: We performed a retrospective and observational study including patients with oral cavity squamous cell carcinoma, treated with induction chemotherapy between January 2010 and December 2018. Outcomes included induction chemotherapy toxicity, treatment response, disease-free survival and overall survival. Results: A total of 108 oral cavity squamous cell carcinoma patients were included. Ninety-six (88.9%) had stage IV disease, while 12 (11.1%) had stage III. Eighty-four patients (80.8%) achieved at least a partial response to induction chemotherapy at clinical evaluation, and 75 (72.1%) at radiological evaluation. Seventy-eight patients have been proposed for subsequent definitive treatments, with no differences obtained in prognosis, when comparing surgical to non-surgical approaches. In patients treated with definitive treatments, improved five-year disease-free survival was obtained if at least a clinical (56.3%; p=0.001) or radiological (52.9%; p=0.001) partial response was achieved after induction chemotherapy. Similarly, superior five-year overall survival was verified for those achieving at least clinical (51.1%; p<0.0001) or radiological (52.6%; p=0.001) partial response. Also, accomplishing a pathologic complete response (n=22.6%) significantly improved disease-free survival (p=0.039) and overall survival (p=0.005). Grade 3 and 4 toxicities were observed in 52 patients (41.8%). Conclusion: Responses to induction chemotherapy predicted prognosis in our population, however important toxicities were observed. Further studies are necessary to identify induction chemotherapy response predictors and subgroups who may benefit from this approach.
引用
收藏
页码:340 / 347
页数:8
相关论文
共 50 条
  • [31] Safety and efficacy of Oro-T oral rinse in oral mucositis during cancer radiotherapy and/or chemotherapy: Cumulative analysis of two studies
    Koushik, Kirthi
    Janaki, M. G.
    Kumawat, Rajesh
    Paramesh, Rangesh
    Palaniyamma, D.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (06) : 1503 - +
  • [32] Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer and comparison with anthracycline-based chemotherapies: Eight-year experience from single centre
    Gupta, D.
    Raina, V
    Rath, G. K.
    Shukla, N. K.
    Mohanti, B. K.
    Sharma, D. N.
    INDIAN JOURNAL OF CANCER, 2011, 48 (04) : 410 - 414
  • [33] Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
    Vetter, Marcus
    Fokas, Spyridon
    Biskup, Ewelina
    Schmid, Thomas
    Schwab, Fabienne
    Schoetzau, Andreas
    Guth, Uwe
    Rochlitz, Christoph
    Zanetti-Dallenbach, Rosanna
    ONCOTARGET, 2017, 8 (43) : 75617 - 75626
  • [34] Safety and Efficacy of Early Oral Feeding after Liver Transplantation with Roux-en-Y Choledochojejunostomy: A Single-Center Experience
    Fakhar, N.
    Sharifi, A.
    Khamneh, A. Chavoshi
    Fard, A. Kasraian
    Heydar, Z.
    Dashti, S. H.
    Jafarian, A.
    INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE, 2020, 11 (03): : 122 - 127
  • [35] EFFICACY OF PEGYLATED LIPOSOMAL DOXORUBICIN-BASED NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER: A SINGLE CENTER EXPERIENCE
    Tsai, I-Chen
    Hung, Chih-Chiang
    CLINICAL AND INVESTIGATIVE MEDICINE, 2021, 44 (01): : E7 - E14
  • [36] Efficacy and safety of trastuzumab-based therapy in combination with different chemotherapeutic regimens in advanced esophagogastric cancer - a single cancer-center experience
    Haag, Georg-Martin
    Apostolidis, Leonidas
    Jaeger, Dirk
    TUMORI, 2014, 100 (03) : 237 - 242
  • [37] Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience
    Pellegrinelli, Julie
    Chevallier, Olivier
    Manfredi, Sylvain
    Dygai-Cochet, Inna
    Tabouret-Viaud, Claire
    Nodari, Guillaume
    Ghiringhelli, Francois
    Riedinger, Jean-Marc
    Popoff, Romain
    Vrigneaud, Jean-Marc
    Cochet, Alexandre
    Aho, Serge
    Latournerie, Marianne
    Loffroy, Romaric
    DIAGNOSTICS, 2021, 11 (01)
  • [38] Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma - A 10-year experience of the geisinger medical center
    Fata, F
    Mirza, A
    Wood, GC
    Nair, S
    Law, A
    Gallagher, J
    Ellison, N
    Bernath, A
    CANCER, 2002, 94 (07) : 1931 - 1938
  • [39] Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients
    Stefani, Alessandro
    Alifano, Marco
    Bobbio, Antonio
    Grigoroiu, Madalina
    Jouni, Rami
    Magdeleinat, Pierre
    Regnard, Jean-Francois
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 140 (02) : 356 - 363
  • [40] Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience
    Lee, Hye In
    Kang, Hyun-Cheol
    Chie, Eui Kyu
    FRONTIERS IN ONCOLOGY, 2022, 12